Obstructive Sleep Apnoea in Patients With Type 1 Diabetes
Obstructive Sleep Apnoea (OSA) in Patients With Type 1 Diabetes (T1D): A Cross-Sectional Study
The primary aim of this study is to assess the relationship between obstructive sleep apnoea (OSA) and cardiac autonomic neuropathy (CAN) in patients with T1D.
The secondary aims of this study are to assess: (1) the prevalence of OSA in patients with T1D; (2) the relationship between OSA and metabolic parameters (such as glycaemic control, blood pressure, lipids and weight) in patients with T1D; (3) the relationship between OSA and diabetes-related microvascular complications (retinopathy, nephropathy, peripheral neuropathy) in patients with T1D; and (4) the potential mechanisms for the relationship between OSA and diabetic-related complications if such a relationship is found.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Obstructive sleep apnoea (OSA) has been reported to be very common in patient with type 2 diabetes (T2D), and this relation is expected as both conditions share obesity as a common risk factor. Despite that several articles have stated that OSA is an independent risk factor for abnormal glucose metabolism, hypertension, and cardiovascular diseases.
In contrast, patients with type 1 diabetes (T1D) are leaner and younger than patients with T2D, so it was expected that OSA might be less common in patients with T1D. However, few studies have reported the prevalence of OSA in T1D with a range between 8 and 46%. The relationship between OSA and diabetes-related vascular disease is poorly explored in patients with T1D. This suggests a mechanism other than obesity may be responsible for OSA in patients with T1D. Therefore, the investigators hypothesized that (1) OSA is related to CAN rather than obesity in patients with T1D. (2) OSA is common in patients with T1D. (3) OSA is associated with worse metabolic profile and microvascular complications in T1D. (4) Oxidative and nitrosative stress are possible mechanisms relating OSA to T1D complication.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Birmingham, Storbritannia, B9 5SS
- Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- T1DM patient aged 18 and above, who was diagnosed more than 4 years ago.
- Able to give informed consent.
- Has sufficient proficiency in English to verbally answer interview questions.
Exclusion Criteria:
- Past medical history of severe respiratory disorders including treated OSA.
- Patients using oxygen supplements.
- Patients with end-stage renal disease receiving dialysis.
- Pregnancy.
- Dementia.
- End stage diseases with life expectancy below 6 months.
- Patients with implantable devices
- Patients with known atrial fibrillation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The relationship between OSA and cardiac autonomic neuropathy (CAN) in patients with T1D.
Tidsramme: Single time point measurement (20- 30 min)
|
CAN will be assessed using heart rate variability (HRV) and spectral analysis. During this test blood pressure and electrocardiogram (ECG) and will be recorded while resting in a sitting down position and during certain manoeuvres that include deep breathing and Valsalva, and standing up. The Result of this outcome will be categorized into normal, borderline, or abnormal. This study is one visit only, and the total duration of the visit is 2-4 hours. The time frame below is the approximate time needed to collect each outcome data. |
Single time point measurement (20- 30 min)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The prevalence of obstructive sleep apnoea in patients with T1D.
Tidsramme: Single time point measurement (over 8 hours) at participant residence
|
Sleep apnoea will be assessed using portable multi-channel home-based sleep device.
|
Single time point measurement (over 8 hours) at participant residence
|
|
The relationship between the presence of OSA and metabolic profile in patients with T1D.
Tidsramme: Single time point measurement (15 min)
|
This outcome will be assessed by comparing the routine assessment results for patients with OSA to patients without OSA.
|
Single time point measurement (15 min)
|
|
The relationship between OSA and the presence of microvascular complications in T1D patients.
Tidsramme: Single time point measurement (1-2 hours)
|
Microvascular complications include diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy.
|
Single time point measurement (1-2 hours)
|
|
The potential mechanisms for the relationship between OSA and diabetic-related complications
Tidsramme: Single time point measurement (about 5 min)
|
Will be assessed using serum and plasma blood samples.
|
Single time point measurement (about 5 min)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Abd Tahrani, MD, NIHR Clinician Scientist at University of Birmingham
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Borel AL, Benhamou PY, Baguet JP, Halimi S, Levy P, Mallion JM, Pepin JL. High prevalence of obstructive sleep apnoea syndrome in a Type 1 diabetic adult population: a pilot study. Diabet Med. 2010 Nov;27(11):1328-9. doi: 10.1111/j.1464-5491.2010.03096.x. No abstract available.
- Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann N Y Acad Sci. 2014 Apr;1311:151-73. doi: 10.1111/nyas.12355. Epub 2014 Mar 14.
- Golbidi S, Badran M, Ayas N, Laher I. Cardiovascular consequences of sleep apnea. Lung. 2012 Apr;190(2):113-32. doi: 10.1007/s00408-011-9340-1. Epub 2011 Nov 3.
- Manin G, Pons A, Baltzinger P, Moreau F, Iamandi C, Wilhelm JM, Lenoble P, Kessler L, Kessler R. Obstructive sleep apnoea in people with Type 1 diabetes: prevalence and association with micro- and macrovascular complications. Diabet Med. 2015 Jan;32(1):90-6. doi: 10.1111/dme.12582. Epub 2014 Sep 25.
- Schober AK, Neurath MF, Harsch IA. Prevalence of sleep apnoea in diabetic patients. Clin Respir J. 2011 Jul;5(3):165-72. doi: 10.1111/j.1752-699X.2010.00216.x. Epub 2010 Jun 30.
- Tahrani AA. Obstructive sleep apnea in patients with diabetes: implications for clinical practice. Diabetes Management. 2015; 5(6):511-23. doi: 10.2217/dmt.15.34.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metabolske sykdommer
- Sykdommer i nervesystemet
- Sykdommer i luftveiene
- Sykdommer i immunsystemet
- Autoimmune sykdommer
- Respirasjonsforstyrrelser
- Søvnforstyrrelser, iboende
- Dyssomnier
- Søvnvåkenforstyrrelser
- Sykdommer i det endokrine systemet
- Tegn og symptomer, luftveier
- Søvnapné syndromer
- Søvnapné, obstruktiv
- Sukkersyke
- Diabetes mellitus, type 1
- Apné
Andre studie-ID-numre
- RG_16-154
- 209532 (Annen identifikator: Integrated Research Approval System (IRAS))
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordFullførtFysisk aktivitet | Mental helse velvære 1 | Kognitiv funksjon 1, sosial | Academic Attainment | Fitness TestingStorbritannia
-
IpsenAvsluttet
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekreft | Solide svulster | Programmert celledød-1 (PD1, PD-1) | Programmert celledød 1 ligand 1 (PDL1, PD-L1) | Programmert celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
SanionaFullført
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionFullført
-
Calliditas Therapeutics ABFullført
-
Rambam Health Care CampusIsrael Science FoundationFullført
-
Alvotech Swiss AGFullført
-
PfizerFullført
-
Stony Brook UniversityFullført